Vasculitis
Recent clinical, regulatory, research and industry developments relating to this disease.
Gut Microbiota and Cardiovascular Disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q1 2028.
- 5 industry developments reported.
- Q1 2028Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial
- Q2 2028A Multicenter Randomized Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO
- Q3 2028A Phase 3, Open-label, Uncontrolled Single-arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Avacopan in Combination With a Rituximab or a Cyclophosphamide-containing Regimen in Children From 6 Years to < 18 Years of Age With Active ANCA-associated Vasculitis (AAV)
- Q4 2036A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Clinical MilestonesViewHide
- 2026-07-01A Multicenter Randomized Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATOResults expected Q2 2028
- 2026-06-18A Phase 3, Open-label, Uncontrolled Single-arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Avacopan in Combination With a Rituximab or a Cyclophosphamide-containing Regimen in Children From 6 Years to < 18 Years of Age With Active ANCA-associated Vasculitis (AAV)Results expected Q3 2028
- 2026-06-18A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisResults expected Q4 2036
- 2026-03-20Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical TrialResults expected Q1 2028
Industry & MarketViewHide
- 2026-09-08Kidney Disease: Improving Global Outcomes (KDIGO) responds to the retraction of the ADVOCATE trial of avacopan for the treatment of ANCA-associated vasculitisTrial news · Kidney International
- 2026-09-04Avacopan in Vasculitis: Uncommon but Severe Liver RisksIndustry · Medscape Medical News
- 2026-08-24U.S. Registry Data Confirm Liver Risk With Controversial Vasculitis DrugIndustry · MedPage Today — Cardiology
- 2026-10-01Corrigendum to “Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis.” Kidney International 2025;108:1158–1169Industry · Kidney International
- 2026-09-15Resident immune cell neighborhoods associate with protein kinase pRIPK3 and fatty acid ligase FACL4 expression during cell injury in ANCA associated vasculitis and lupus nephritisIndustry · Kidney International
- 2026-10-01IndustryCorrigendum to “Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis.” Kidney International 2025;108:1158–1169Industry · Kidney International
- 2026-09-15IndustryResident immune cell neighborhoods associate with protein kinase pRIPK3 and fatty acid ligase FACL4 expression during cell injury in ANCA associated vasculitis and lupus nephritisIndustry · Kidney International
- 2026-09-08IndustryKidney Disease: Improving Global Outcomes (KDIGO) responds to the retraction of the ADVOCATE trial of avacopan for the treatment of ANCA-associated vasculitisTrial news · Kidney International
- 2026-09-04IndustryAvacopan in Vasculitis: Uncommon but Severe Liver RisksIndustry · Medscape Medical News
- 2026-08-24IndustryU.S. Registry Data Confirm Liver Risk With Controversial Vasculitis DrugIndustry · MedPage Today — Cardiology
- 2026-08-12ClinicalA Randomised, Double-blind, Active-controlled 52-week Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Patients Receiving Standard of Care Therapy (MANDARA Study)Results posted
- 2026-07-01ClinicalA Multicenter Randomized Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATOResults expected Q2 2028
- 2026-06-18ClinicalA Phase 3, Open-label, Uncontrolled Single-arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Avacopan in Combination With a Rituximab or a Cyclophosphamide-containing Regimen in Children From 6 Years to < 18 Years of Age With Active ANCA-associated Vasculitis (AAV)Results expected Q3 2028
- 2026-06-18ClinicalA Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisResults expected Q4 2036
- 2026-03-20ClinicalMaintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical TrialResults expected Q1 2028
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Leading journals1
- Circulation research1
Leading researchers3
- Hazen SL1
- Weeks TL1
- Witkowski M1
Affiliations (unnormalised)3
- Center for Microbiome and Human Health (M.W.1
- Heart and Vascular Institute (S.L.H.)1
- Lerner Research Institute (M.W.1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.